Actualités Selvita Sa - 0RKT | Actions London Stock Exchange

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR...

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR...

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit PR Newswire KRAKOW, Poland, Sept. 23...

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress PR Newswire KRAKOW...

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting PR Newswire KRAKOW...

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with...

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting PR Newswire KRAKOW, Poland, Nov. 2...

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update PR Newswire KRAKOW, Poland, Sept. 28, 2022 KRAKOW...

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress PR...

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting PR Newswire KRAKOW, Poland, March 8, 2022 KRAKOW...

Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology As...

Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. Phase...

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metas...

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced...

Selvita completes acquisition of Fidelta from Galapagos

Selvita completes acquisition of Fidelta from Galapagos PR Newswire MECHELEN, Belgium and KRAKOW, Poland, Jan. 4, 2021 MECHELEN, Belgium and...

Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be publish...

Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American...

Selvita reports strong financial results for H1 2020 and a record backlog

Selvita reports strong financial results for H1 2020 and a record backlog PR Newswire KRAKOW, Poland, Sept. 10, 2020 KRAKOW, Poland, Sept. 10...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Selvita Sa (0RKT)

Votre Hub pour des idées et discussions en direct en temps réel

0RKT Actualités

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology As...

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metas...

Selvita completes acquisition of Fidelta from Galapagos

Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be publish...

Selvita reports strong financial results for H1 2020 and a record backlog

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Selvita Sa (0RKT) Actualités

Selvita Sa (0RKT)

Votre Hub pour des idées et discussions en direct en temps réel

0RKT Actualités

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology As...

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metas...

Selvita completes acquisition of Fidelta from Galapagos

Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be publish...

Selvita reports strong financial results for H1 2020 and a record backlog

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités